跳至主要内容
临床试验/JPRN-UMIN000001916
JPRN-UMIN000001916已完成3 期

Randomized trial of platinum based combination chemotherapy with or without Zoledronic acid as first line therapy for non-small cell lung cancer with bone metastases stratified by bone marker (TORG0706). - Randomized trial of platinum based combination chemotherapy with or without Zoledronic acid as first line therapy for non-small cell lung cancer with bone metastases stratified by bone marker (TORG0706).

Thoracic Oncology Research Group (TORG)0 个研究点目标入组 160 人开始时间: 2009年5月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Sever allergy 2. Required radiation or operation for bone metastases 3. Hypercalcemia 4. History of using bisphosphonate 5. Massive pleural effusion, ascites and pericardial effusion required drainage 6. Symptomatic brain metastasis 7. Patients with serious infections or suspected infections 8. Patients who need dental treatment 9. Active ineterstitial pneumonitis 10. Active concomitant malignancy 11. Pregnant or lactating women 12. Acute Myocardial Infarction within 6 months. 13. Patinets with uncontroled complications 14. Psychological symptoms not suitable for this study 15. other conditions not suitable for this study

研究者

发起方
Thoracic Oncology Research Group (TORG)

相似试验